MHRA and NICE launch aligned pathway for faster medicine regulation
The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) will make…
19 Mar 2026
Quintessence debuts first ‘living’ artificial cell for CGT bio-separation
Quintessence Biotech has launched a bio-separation tool to reduce the manufacturing bottleneck suffered by cell and gene therapies (CGTs), creating the first “living” artificial cell. DACS is a biomimetic lipid…
19 Mar 2026
Huntington’s gene therapy research has reached a turning point, expert says
Despite unanticipated regulatory hurdles following promising clinical results with a novel investigational treatment for Huntington’s Disease, the significance of the gene therapy’s impact remains strong, as per an expert. Earlier…
18 Mar 2026
Calls for change as access to cell and gene therapies in the Netherlands falls short
The Netherlands is falling behind other European countries in providing access to advanced therapy medicinal products (ATMPs) according to Peter Fassler, Director of Market Access at Gilead Sciences, as indicated…
18 Mar 2026
Excalipoint debuts with $68.7m to progress TCE pipeline
Chinese biotech Excalipoint Therapeutics is looking to progress its pipeline of T-cell engager (TCE) therapies in immunology and oncology as it emerges with $68.7m in seed funding under its wing.…
18 Mar 2026
GSK prepared for potential expansion of meningitis vaccine schedule amid UK outbreak
Amid an ongoing outbreak of meningococcal disease in Kent, England, GSK has said it is ready to work with UK health authorities to widen its meningitis vaccine’s slot on the…
18 Mar 2026
Navigating the valley of death: a how-to from an investor’s perspective
In a crowded biotech landscape full of potential, especially in advanced therapeutic medicinal products (ATMPs), companies must differentiate themselves from their competitors to secure much-needed capital from investors. This can…